Host |
Mouse |
Klon |
SMP14 |
Format |
Purified |
Methode |
F, P, IP |
Vorbehandlung |
EDTA pH 8,0 oder pH 9,0 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:200 - 1:500 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2 |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
SMP14 |
100 µg |
Purified |
RUO |
613-0099 |
-
|
Host |
Mouse |
Klon |
SMP14 |
Format |
Purified |
Methode |
F, P |
Vorbehandlung |
EDTA pH 8,0 oder pH 9,0 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:200 - 1:500 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2 |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
SMP14 |
20 µg |
Purified |
RUO |
613-0100 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to amino acids 177-195 of mouse mdm2 |
MDM2 (Murine Double Minute 2)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
613-0355 |
-
|
Host |
Mouse |
Klon |
SMP14 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Liposarcoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
1 ml |
Concentrate |
CE/IVD |
Z2189ML |
-
|
Host |
Mouse |
Klon |
SMP14 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Liposarcoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
7 ml |
Ready-to-use |
CE/IVD |
Z2189MP |
-
|
Host |
Mouse |
Klon |
SMP14 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Liposarcoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
0.5 ml |
Concentrate |
CE/IVD |
Z2189MS |
-
|
Host |
Mouse |
Klon |
SMP14 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Liposarcoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Amino acids 154-167 of MDM2 of human origin |
Lokalisation |
Nucleus |
MDM2 (Murine Double Minute 2)
|
Zeta Corporation |
SMP14 |
0.1 ml |
Concentrate |
CE/IVD |
Z2189MT |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Melanoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3114A |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Melanoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3114B |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3114G7 |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
6 ml |
Ready-to-use |
CE/IVD |
API3114AA |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic |
Melan A
|
Biocare Medical |
A103 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3114G |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or melanoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant MART-1 protein |
Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
1.0 ml |
Concentrate |
CE/IVD |
Z2052ML |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or melanoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant MART-1 protein |
Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
7 ml |
Ready-to-use |
CE/IVD |
Z2052MP |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or melanoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant MART-1 protein |
Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
0.5 ml |
Concentrate |
CE/IVD |
Z2052MS |
-
|
Host |
Mouse |
Klon |
A103 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin or melanoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant MART-1 protein |
Lokalisation |
Cytoplasm |
Melan-A (MART-1)
|
Zeta Corporation |
A103 |
0.1 ml |
Concentrate |
CE/IVD |
Z2052MT |
-
|
Host |
Mouse |
Klon |
PNL2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, Cell Membrane |
Melanoma
|
Diagnostic Biosystems |
PNL2 |
1 ml |
Concentrate |
CE/IVD |
MOB421 |
-
|
Host |
Mouse |
Klon |
PNL2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, Cell Membrane |
Melanoma
|
Diagnostic Biosystems |
PNL2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB421-01 |
-
|
Host |
Mouse |
Klon |
PNL2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:10 - 1:25 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, Cell Membrane |
Melanoma
|
Diagnostic Biosystems |
PNL2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB421-05 |
-
|
Host |
Mouse |
Klon |
HMB45+M2-7C10+M2-9E3+T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse Ig |
Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
1 ml |
Concentrate |
CE/IVD |
MOB428 |
-
|
Host |
Mouse |
Klon |
HMB45+M2-7C10+M2-9E3+T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse Ig |
Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
0.1 ml |
Concentrate |
CE/IVD |
MOB428-01 |
-
|
Host |
Mouse |
Klon |
HMB45+M2-7C10+M2-9E3+T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse Ig |
Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
0.5 ml |
Concentrate |
CE/IVD |
MOB428-05 |
-
|
Host |
Mouse |
Klon |
HMB45+M2-7C10+M2-9E3+T311 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse Ig |
Lokalisation |
Cytoplasm |
Melanoma Cocktail (HMB45 + MART-1 + Tyrosinase)
|
Diagnostic Biosystems |
HMB45+M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
PDM146 |
-
|
Host |
Mouse |
Klon |
HMB-45 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
1.0 ml |
Concentrate |
CE/IVD |
Z2088ML |
-
|
Host |
Mouse |
Klon |
HMB-45 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
7 ml |
Ready-to-use |
CE/IVD |
Z2088MP |
-
|
Host |
Mouse |
Klon |
HMB-45 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
0.5 ml |
Concentrate |
CE/IVD |
Z2088MS |
-
|
Host |
Mouse |
Klon |
HMB-45 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Extract of pigmented melanoma metastases from lymph nodes |
Lokalisation |
Cytoplasm |
Melanosome
|
Zeta Corporation |
HMB-45 |
0.1 ml |
Concentrate |
CE/IVD |
Z2088MT |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:25-100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A suspension of mesothelioma cells of human origin |
Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2233ML |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A suspension of mesothelioma cells of human origin |
Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2233MP |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:25-100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A suspension of mesothelioma cells of human origin |
Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2233MS |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:25-100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A suspension of mesothelioma cells of human origin |
Lokalisation |
Cytoplasm |
Mesothelial Cells
|
Zeta Corporation |
HBME-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2233MT |
-
|
Host |
Mouse |
Klon |
MSLN-15C11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, fallopian tube |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Membran for mesotheliomas, cytoplasm for carcinomas |
Mesothelin
|
Biocare Medical |
MSLN-15C11 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3175A |
-
|
Host |
Mouse |
Klon |
MSLN-15C11 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, fallopian tube |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Membran for mesotheliomas, cytoplasm for carcinomas |
Mesothelin
|
Biocare Medical |
MSLN-15C11 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3175B |
-
|
Host |
Mouse |
Klon |
MSLN-15C11 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, fallopian tube |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Membran for mesotheliomas, cytoplasm for carcinomas |
Mesothelin
|
Biocare Medical |
MSLN-15C11 |
6 ml |
Ready-to-use |
CE/IVD |
API3175AA |
-
|
Host |
Rabbit |
Klon |
YP158 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:10 - 1:15 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
1 ml |
Concentrate |
CE/IVD |
RMAB107 |
-
|
Host |
Rabbit |
Klon |
YP158 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:10 - 1:15 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB107-01 |
-
|
Host |
Rabbit |
Klon |
YP158 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:10 - 1:15 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB107-05 |
-
|
Host |
Rabbit |
Klon |
YP158 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD107 |
-
|
Host |
Rabbit |
Klon |
YP158 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to C-terminus of human mesothelin protein |
Lokalisation |
Cell membrane |
Mesothelin
|
Diagnostic Biosystems |
YP158 |
25 ml |
Ready-to-use |
CE/IVD |
RMPD107-25 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM25 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
1 ml |
Concentrate |
CE/IVD |
Z2353ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM25 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
7 ml |
Ready-to-use |
CE/IVD |
Z2353MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM25 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
0.5 ml |
Concentrate |
CE/IVD |
Z2353MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM25 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human mesothelin (MSLN) protein fragment (around aa 273-407) |
Lokalisation |
Cytoplasm |
Mesothelin
|
Zeta Corporation |
ZM25 |
0.1 ml |
Concentrate |
CE/IVD |
Z2353MT |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:15 - 1:25 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
1 ml |
Concentrate |
CE/IVD |
MOB349 |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:15 - 1:25 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB349-01 |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Mesothelioma |
Verdünnung |
1:15 - 1:25 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB349-05 |
-
|
Host |
Mouse |
Klon |
HBME-1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Mesothelioma |
Verdünnung |
- |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
Mesothelioma
|
Diagnostic Biosystems |
HBME-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM134 |
-
|
Host |
Mouse |
Klon |
ZM314 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma, glioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /k |
Verdünnung |
Purified His-tagged MGMT protein |
Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
1 ml |
Concentrate |
CE/IVD |
Z2618ML |
-
|
Host |
Mouse |
Klon |
ZM314 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma, glioma |
Verdünnung |
- |
Isotyp |
IgG1 /k |
Verdünnung |
Purified His-tagged MGMT protein |
Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
7 ml |
Concentrate |
CE/IVD |
Z2618MP |
-
|
Host |
Mouse |
Klon |
ZM314 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma, glioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /k |
Verdünnung |
Purified His-tagged MGMT protein |
Lokalisation |
Nucleus |
MGMT
|
Zeta Corporation |
ZM314 |
0.5 ml |
Concentrate |
CE/IVD |
Z2618MS |
-
|